# BridgeBio Pharma Q2 financial performance > Live situation record from CLSTR: https://clstr.news/situations/bridgebio-pharma-q2-financial-performance > Updated: 2026-08-10T22:06:58.000Z. Sources: 4. Developments: 2. BridgeBio Pharma reported second-quarter results highlighting significant growth in net product revenue, reaching $222.4 million compared to $71.5 million in the previous year. This growth was primarily driven by the ATTR cardiomyopathy treatment, Attruby. CEO Neil Kumar described the company as being in a “transition period” marked by the commercial success of Attruby and the progression of late-stage programs. The company reaffirmed its global sales guidance for Attruby and Beyonttra, projecting worldwide net sales to exceed $1 billion for the year. To fund commercial and pipeline investments, BridgeBio completed a $1 billion preferred equity raise. The company is also preparing for three potential product launches by mid-2027, with regulatory submissions currently underway for programs targeting achondroplasia, autosomal dominant hypocalcemia type 1, and limb-girdle muscular dystrophy type 2I. In subsequent financial reporting, BridgeBio reported revenue of $243.68 million, which exceeded the $220.91 million estimate, though its earnings per share (EPS) of ($0.78) missed the consensus estimate of ($0.58). Management noted that Attruby’s growth is being led by first-line, treatment-naive patients and highlighted data suggesting the treatment may offer kidney-protective effects. ## Timeline ### 2026-08-10: BridgeBio Pharma reports strong Q2 growth driven by Attruby BridgeBio Pharma reported strong Q2 results, led by Attruby revenue growth, and reaffirmed its $1 billion+ annual sales guidance while advancing three late-stage programs toward regulatory review. 4 sources. https://clstr.news/cluster/bridgebio-pharma-reports-strong-q2-growth-driven-by-attruby ### 2026-08-10: Various companies report quarterly earnings and financial results Multiple companies, including Sutro Biopharma, Legend Biotech, and BridgeBio Pharma, have released quarterly earnings reports, showing a mix of missed expectations and revenue growth. 3 sources. https://clstr.news/cluster/bridgebio-pharma-reports-quarterly-earnings-miss --- Cite as: BridgeBio Pharma Q2 financial performance. CLSTR, https://clstr.news/situations/bridgebio-pharma-q2-financial-performance